This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
strategies, patients entered the Markov model at the end of year 1 (which was considered to be the treatment year). The model estimated blood pressure-specific incidences of myocardial infarction, stroke and chronic renal deficiencies. The patients were followed up for life.
Outcomes assessed in the review
The following input parameters were included in the model: the incidence of renal artery stenosis, the sensitivity and specificity of the three imaging tests, the incidence of complications (e.g. contrast-induced nephropathy requiring dialysis and associated mortality rate), and mortality and morbidity rates associated with diagnostic conventional angiography and renal arterial stenting.
Blood pressure response to renal artery stent placement was estimated by accounting for the incidence of restenosis and the response to the addition of a third and a fourth medication in renal artery stenosis. Improvement was characterised by a diastolic blood pressure (DBP) >90 mmHg and some improvement by a DBP of 90 to 100 mmHg. Blood pressurespecific incidences of myocardial infarction stroke and chronic renal failure were measured for a DBP <90 mmHg, a DBP of 90 to 100 mmHg or when the DBP was >110 mmHg. Immediate and yearly mortality rates associated with stroke and myocardial infarction, and mortality rate associated with chronic renal failure, were also assessed.
Most of the values were derived from the literature. The authors estimated the blood pressure-specific incidences of myocardial infarction, stroke and chronic renal failure using a technique described elsewhere (see 'Other Publications of Related Interest' below for bibliographic details). Mortality rates associated with chronic renal failure were derived from survival estimates of individuals on dialysis for renovascular disease as reported in a published study (see 'Other Publications of Related Interest' below for bibliographic details).
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Overall, the authors cited 11 primary studies as sources of the effectiveness evidence.
Methods of combining primary studies
It was unclear whether the authors combined the results of the primary studies.
Investigation of differences between primary studies
Results of the review
The incidence of renal artery stenosis was 0.20 (range: 0.10 to 0.80).
The sensitivity of CT angiography was 0.96 (range: 0.88 to 1.00) and the specificity was 0.96 (range: 0.65 to 0.97).
The sensitivity of MR angiography was 0.98 (range: 0.88 to 1.00) and the specificity was 0.94 (range: 0.75 to 1.00).
The sensitivity and specificity of conventional angiography were both 0.99 (range: 0.80 to 1.00).
The incidence rate of contrast-induced nephropathy requiring dialysis was 0.0018 (range: 0.0009 to 0.004) and the associated mortality rate was 0.545 (range: 0.25 to 1.00).
The mortality and morbidity rate associated with diagnostic conventional angiography were 0.0004 (range: 0.0002 to 0.0008) and 0.091 (range: 0.045 to 0.20), respectively.
The mortality and morbidity rates associated with renal arterial stenting were 0.0043 (range: 0.002 to 0.008) and 0.047 (range: 0.023 to 0.09), respectively.
The incidence rate of restenosis after renal artery stent placement was 0.11 (range: 0.05 to 0.20). The rate of improvement was 0.18 (range: 0.08 to 0.32) and the rate of some improvement was 0.53 (range: 0.30 to 1.00).
The rate of improvement after the addition of a third medication in renal artery stenosis was 0.10 (range: 0.08 to 0.30) and the rate of some improvement was 0.40 (range: 0.20 to 0.80).
The rate of improvement after the addition of a fourth medication in renal artery stenosis was 0.10 (range: 0.05 to 0.30) and the rate of some improvement was 0.05 (range: 0.025 to 0.10).
The incidence rate of myocardial infarction varied from 0.0032/year (range: 0.0015 to 0.006) when the DBP was <90 mmHg to 0.0095/year (range: 0.005 to 0.02) when the DBP was >90 mmHg. The associated immediate and yearly mortality rates were 0.15 (range: 0.07 to 0.3) and 0.0311 (range: 0.015 to 0.06), respectively.
The incidence rate of stroke varied from 0.0008/year (range: 0.0004 to 0.0016) when the DBP was <90 mmHg to 0.0072/year (range: 0.0035 to 0.014) when the DBP was >90 mm Hg. The associated immediate and yearly mortality rates were 0.19 (range: 0.1 to 0.4) and 0.0201 (range: 0.01 to 0.04), respectively.
The incidence rate of chronic renal failure varied from 0.002/year (range: 0.0010 to 0.0050) when the DBP was <90 mmHg to 0.0462/year (range: 0.02 to 0.10) when the DBP was >90 mmHg. The associated mortality rate was 0.30 (range: 0.15 to 0.60).
Methods used to derive estimates of effectiveness
Some estimates of effectiveness were supplemented by authors' assumptions.
Estimates of effectiveness and key assumptions
owing to a lack of existing data in the literature, the authors assumed the sensitivity and specificity of conventional angiography were both 99%.
Measure of benefits used in the economic analysis
The measures of benefits used were the life-years (LYs) lived, quality-adjusted life-years (QALYs) lived and testrelated disutility-adjusted QALYs.
The utilities for LYs saved were derived from two published studies that used the time trade-off technique in patients with myocardial infarction and with stroke, respectively (see 'Other Publications of Related Interest' below for bibliographic details). It was reported that in combinations of conditions, the lowest quality adjustor was used. This was based on authors' assumptions and was justified appropriately.
Test-dependent short-term disutilities were derived from published studies that used risk-based assessment with the time trade-off technique in MRH patients diagnosed by MR and conventional angiography (see 'Other Publications of Related Interest' below for bibliographic details). The authors assumed that test-related disutility of CT angiography was equal to that of MR angiography, whilst acknowledging the fact that the assumption was probably an underestimate. Test-related disutilities were incorporated into the cost-effectiveness analysis by calculating the willingness-to-pay according to a published study, and multiplying the test-related disutility by the difference between the qualities of life before and after treatment for hypertension.
Direct costs
Health service costs were included. The costs included in the analysis focused on the costs of the imaging techniques (CT, MR and conventional angiography), renal artery stent placement, myocardial infarction (per patient per year), stroke (per patient per year), dialysis (per patient per year), antihypertensive medication (with three and four antihypertensives per year) and annual clinic evaluation. The costs were either derived from actual data (1999 Medicare and Diagnosis-related group reimbursements for south-eastern Michigan) or from the literature. The unit costs were reported. The costs were discounted at an annual rate of 3%, which was appropriate as the outcomes were calculated for the patient's lifetime. All costs were reported for 1999 levels and appear to have been estimated per patient (in some cases this was explicitly stated).
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
Indirect costs were reported per patient per year. The costs included were lost wages due to morbidity (myocardial infarction, stroke, chronic renal failure and hypertension), which were derived from the literature, and future earnings lost due to premature death (derived from a published study using human capital valuation of a statistical LY). The unit costs were reported. All costs were discounted at an annual rate of 3%, which was appropriate since the costs were incurred over a patient's lifetime. All costs were reported for 1999 levels.
Currency

US dollars ($).
Sensitivity analysis
A sensitivity analysis was carried out on all input parameters to investigate variability in the data. The type of sensitivity analysis was not explicitly stated, but it appears to have been a one-way analysis that was carried out after adjusting for quality of life and test-related disutility. The variable ranges tested were based on published data. Where data were not available in the literature, the authors conducted an analysis in which the input parameters were varied by 50% (lower limit) and 200% (upper limit) of the base-case value.
